Abstract
Ticagrelor is a new oral antagonist of the platelet P2Y12 receptor that offers several potential advantages compared to clopidogrel including faster and more effective inhibition of platelet aggregation. Ticagrelor has been compared to clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial in a broad population of patients with acute coronary syndrome showing a reduction of the 12-month risk of death from vascular causes, myocardial infarction and stroke without increasing the overall risk of major bleeding. In a subanalysis of the PLATO trial focusing on patients with ST-elevation myocardial infarction, ticagrelor results were consistent with those of the overall trial. Additionally, possible pleiotropic effects of ticagrelor, including an appealing interaction with adenosine, might constitute a specific advantage in this particular subset of patients
Keywords: Ticagrelor, ST-elevation myocardial infarction, PLATO, P2Y12 receptor, clopidogrel, platelet aggregation, acute coronary syndrome, thrombolysis, percutaneous coronary intervention, thienopyridine
Current Vascular Pharmacology
Title:Ticagrelor in ST-Elevation Myocardial Infarction
Volume: 10 Issue: 4
Author(s): Gregory A. Sgueglia, Giuseppe Tarantini and Giampaolo Niccoli
Affiliation:
Keywords: Ticagrelor, ST-elevation myocardial infarction, PLATO, P2Y12 receptor, clopidogrel, platelet aggregation, acute coronary syndrome, thrombolysis, percutaneous coronary intervention, thienopyridine
Abstract: Ticagrelor is a new oral antagonist of the platelet P2Y12 receptor that offers several potential advantages compared to clopidogrel including faster and more effective inhibition of platelet aggregation. Ticagrelor has been compared to clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial in a broad population of patients with acute coronary syndrome showing a reduction of the 12-month risk of death from vascular causes, myocardial infarction and stroke without increasing the overall risk of major bleeding. In a subanalysis of the PLATO trial focusing on patients with ST-elevation myocardial infarction, ticagrelor results were consistent with those of the overall trial. Additionally, possible pleiotropic effects of ticagrelor, including an appealing interaction with adenosine, might constitute a specific advantage in this particular subset of patients
Export Options
About this article
Cite this article as:
A. Sgueglia Gregory, Tarantini Giuseppe and Niccoli Giampaolo, Ticagrelor in ST-Elevation Myocardial Infarction, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812728
DOI https://dx.doi.org/10.2174/157016112800812728 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Generation of the Fluorescent HMGB1-GFP Fusion Protein in Insect Cells and Evaluation of its Immunogenicity in Two Mice Models
Protein & Peptide Letters From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19
Combinatorial Chemistry & High Throughput Screening Hesperetin Liposomes for Cancer Therapy
Current Drug Delivery A Yeast Extract High in Bioactive Peptides has a Blood-Pressure Lowering Effect in Hypertensive Model
Current Medicinal Chemistry Cholesterol Homeostasis and Liver X Receptor (LXR) in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Metabolic Syndrome in HIV-patients in Antiretroviral Therapy
Current HIV Research Relationship of Dietary Habits and Obesity to Oxidative Stress in Palauan People: Compared with Japanese and Mongolian People
Current Aging Science Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) AMPA Receptor Antagonists as Potential Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery Recent Advances and Applications in Synchrotron X-Ray Protein Footprinting for Protein Structure and Dynamics Elucidation
Protein & Peptide Letters The Role of Transesophageal Echocardiography in the Intraoperative Period
Current Cardiology Reviews microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA Impact of Metabolic Surgery on Type-2 Diabetes Remission
Current Diabetes Reviews Chlorambucil Cytotoxicity Reduction in Rats Through Bone Marrow, An In vivo Study
Anti-Cancer Agents in Medicinal Chemistry Regenerative Potential of Stem Cells Derived from Human Exfoliated Deciduous (SHED) Teeth during Engineering of Human Body Tissues
Current Stem Cell Research & Therapy Computational Study and Synthesis of a New Class of Anticonvulsants with 6 Hz Psychomotor Seizure Test Activity: 2-(1,3-benzodioxol-5-yloxy)- N'-[substituted]-acetohydrazides
Medicinal Chemistry